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Background: Small airways dysfunction and inﬂammation contribute signiﬁcantly to the clinical impact
of asthma, yet conventional methods of assessing airways function in the clinic cannot reliably evaluate
its presence. However, most recently, promising methods of assessment are being utilised.
Methods: We conducted a systematic literature review, using PubMed, with the aim of determining the
prevalence of small airways disease in adult patients with asthma. We ascertained how small airways
disease prevalence compared between different studies when measured using distinct techniques of
small airways assessment.
Results: Fifteen publications were identiﬁed determining the prevalence of small airways disease in
asthma. Methods of assessments included impulse oscillometry, spirometry, body plethysmography,
multiple-breath nitrogen washout, and high-resolution computed tomography. These studies used
differing inclusion characteristics and recruited patients with a broad range of asthma severity, yet
collectively they reported an overall prevalence of small airways disease of 50e60%. Small airways
disease was present across all asthma severities, with evidence of distal airway disease even in the
absence of proximal airway obstruction.
Conclusions: Small airways disease is highly prevalent in asthma, even in patients with milder disease.
Given the clinical impact of small airways disease, its presence should not be underestimated or over-
looked as part of the daily management of patients with asthma.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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The small airways are usually deﬁned as having an internal
diameter smaller than 2 mm [1], and are generally understood to
include the small airways conducting zone and the acinar zone (the
terminal and respiratory bronchioles and alveolar ducts). Conven-
tional methods of assessing airways function such as forced expi-
ratory volume in 1 s (FEV1) and peak expiratory ﬂow (PEF), are
inﬂuenced by the degree of airway resistance (which is largely due
to the larger, proximal airways), and so cannot reliably and sensi-
tively evaluate small airways obstruction. However, more recently,
distinct physiological and imaging techniques are allowing an
assessment of the ‘quiet zone’, and it is clear that small airways
disease (SAD) contributes signiﬁcantly to the clinical impact of
asthma [2]. For example, small airways inﬂammation has been
shown to correlate with symptoms in patients with nocturnal
asthma [3], and with the Asthma Control Test (ACT) score even in
patients with asthma of mild severity [4]. Furthermore, it has been
observed that increased small airways resistance correlates with
worsening health status [5], dyspnoea [5], and asthma exacerba-
tions [6].
Moreover, pharmacological interventions have been developed
that allow the delivered drug to reach the small airways, such as
small particle (<2 micron) formulations [7]. These have been
shown to improve SAD and improve outcomes in patients with
asthma [8]. Vos et al. reported a statistically signiﬁcant correlation
(p ¼ 0.004) between changes in small airways volume, determined
from high-resolution computed tomography (HRCT), and patients’
asthma control following treatment with a small particle combi-
nation inhaled corticosteroid (ICS) and long-acting b2-agonist
(LABA) [9]. Hoshino treated patients who had mild-persistent
asthma with conventional-particle ICS monotherapy for 8 weeks,
and then randomized them to either continue conventional-
particle ICS or switch to a small-particle ICS [10]. The small-
particle ICS led to a signiﬁcant improvement in small airways
resistance, determined by impulse oscillometry (IOS), and the pa-
tients’ ACT score, which was not observed with conventional-
particle ICS treatment. Farah et al. found that baseline small air-
ways ventilation, assessed usingmultiple-breath nitrogenwashout,
predicted patient’s symptomatic response to ICS titration [11]; and
changes in the Asthma Control Questionnaire (ACQ)-5 score
correlated with changes in small airways ventilation [12]. Recently,
‘real-life’ studies have also demonstrated better asthma control
with small particle ICS monotherapy or ICS/LABA combination
formulations compared with conventional-particle aerosols
[8,13,14].
1.1. Search methodology
Given the increasing awareness of the importance of SAD in
asthma management, we conducted a systematic literature review
to determine the prevalence of SAD in adult patients with asthma,
and to ascertain how SAD prevalence compared between different
studies when measured using different methods of assessment. A
number of other reviews have considered the practical application
of these techniques in determining SAD [2,7,8], and so this was not
an aim of this current work. The literature search, using PubMed,
was conducted by one of the researchers on 21 December 2015 (for
manuscripts published up to that date) with the phrase “smallairways” OR “distal lung” OR “peripheral airways” AND asthma (with
the only limit applied being for English language). Abstracts were
scanned for potential relevance (i.e., potentially containing data
from a clinical trial on the prevalence of SAD in adults with asthma),
with shortlisted manuscripts reviewed in detail for data on the
percentage of the populationwith SAD (as deﬁned by the authors of
each source manuscript), either using the percentages quoted in
the manuscripts, or calculating a percentage using quoted patient
numbers. A second researcher then performed a quality check on
the shortlisted manuscripts, and discussed any discrepancies with
the ﬁrst researcher. The data are reported for individual studies
with no data synthesis, and the Cochrane Collaboration’s tool was
used to assess the risk of bias. The search protocol is registered on
the PROSPERO register of systematic reviews, registration number
CRD42015026971. Only data reporting on the prevalence of small
airways disease were assessed.
2. Overview of reported techniques
2.1. Spirometry, plethysmography and volume assessment
Premature airways closure is a feature of SAD, resulting in air-
trapping and hyperinﬂation. Forced vital capacity (FVC) is an indi-
rect marker, with reduced values indicating the presence of SAD
[15]. The difference between slow vital capacity (SVC) and FVC has
also been utilised as an indirect marker of air-trapping [16]. In
addition, lower values of forced expiratory ﬂow (FEF) from 25 to
75%, or at 50% or 75% (FEF25e75%, FEF50%, FEF75%) have been reported
to suggest the presence of small airways obstruction [16]. However,
these parameters may simply reﬂect airﬂow heterogeneity, and
should ideally be supported by other physiological or imaging in-
vestigations to conﬁrm the presence of SAD [16].
Body plethysmography is more sensitive for detecting small
airways obstruction than the forced expiratory ﬂow measures [17].
Higher values of functional residual capacity (FRC), residual volume
(RV), or the ratio of RV to total lung capacity (TLC) indicate lung
hyperinﬂation, which is suggestive of the presence of SAD.
Finally, some researchers have used either closing capacity (CC)
or closing volume (CV) to determine the presence of small airways
disease, indicated by an increase in either CV/VC or CC/TLC.
2.2. Impulse oscillometry
IOS utilises pressure applied to the airways at a range of fre-
quencies, and components of respiratory impedance are measured,
including resistance and reactance [18]. Resistance at 5 Hz (R5) and
20 Hz (R20), respectively, represent total airway resistance and
proximal airway resistance. The difference between these two
values can be calculated (R5eR20), with higher values suggesting
the presence of SAD.
2.3. Multiple-breath nitrogen washout
Gas is transported in the lung by either convection in the larger
airways, or diffusion in the smaller acinar airways, with the border
between these two mechanisms of gas transport corresponding to
the end of the terminal respiratory bronchioles. Multiple-breath
nitrogen washout utilises this to assess ventilation heterogeneity,
with Scond associated with the conductive airways, and Sacin with
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erogeneity, suggestive of distal acinar SAD; SAD can also contribute
to elevated Scond values.
2.4. High-resolution computed tomography
Individual acini are not generally visible using HRCT. However,
air-trapping can be detected using HRCT conducted at end-
expiration, seen as parenchymal areas with a less than normal in-
crease in attenuation [20]. Diffuse or subtle air-trapping may
require the operator to compare inspiratory and expiratory scans.
3. Results
Of 837 articles identiﬁed, ﬁfteen had relevant content (Fig. 1 and
Table 1) [21e35]. Eleven of these were identiﬁed from the PubMed
search; one was quoted in the discussion section of an identiﬁed
article; and the authors of the current manuscript suggested three
additional publications that were not identiﬁed in this search. The
prevalence of SAD in the individual studies is summarized in Fig. 2.
Interestingly, although 24 studies were identiﬁed that used exhaled
nitric oxide to assess airways function, all presented data only as
mean values, rather than the percentage above (or below) a spec-
iﬁed cut-point, and so SAD prevalence could not be calculated.
Using the Cochrane Collaboration’s tool for assessing the risk ofFig. 1. PRISMA 2009bias, in terms of the data reported here, we consider the risk of bias
to be low in nine of the studies, and low-to-medium in the
remainder (due to possible selection bias). It should be noted that
the majority of the studies did not report blinding of participants,
personnel or outcome assessments, but given the outputs of in-
terest are physiological, this is not considered to be a source of bias.3.1. Prevalence using spirometry, plethysmography or volume
assessments
Manoharan et al. used data from 442 patients undergoing
screening for clinical trials. A cut-point of 60% of predicted for
FEF25e75% was used to deﬁne the presence of SAD e which the
authors described as arbitrary [24]. A total of 238 patients (54%) had
values <60%; these patients were signiﬁcantly older and with a
worse FEV1 than those without SAD.
Jain et al. reviewed lung function data from 321 patients with
predominantly mild airﬂow obstruction (only 25% having FEV1
<80% of predicted) [23]. There was a high prevalence of air trap-
ping, with 52% of the patients having abnormal RV (deﬁned as
>100% predicted), and 57% having abnormal RV/TLC ratios (deﬁned
as >35%). Furthermore, in the patients with FEV1 <90% predicted,
there was a trend to increasing RV and RV/TLC with decreasing
FEV1.
Perez and colleagues analysed lung function data from 222ﬂow diagram.
Table 1
Summary of studies assessing prevalence of small airways disease.
Method Study Population Endpoint
Asthma severity Sample size Age (years)a FEV1 (percent predicted)a
Spirometry, plethysmography
and volume assessment
Manoharan et al. [24] All severities n ¼ 442 42 ± 15 86 ± 20 FEF25e75% <60% predicted
Jain et al. [23] No restriction n ¼ 321 47.9 ± 13.6 84.9 ± 20.1 RV >100% predicted
RV/TLC >35
Perez et al. (2013) [25] Moderate to severe; without
proximal airways obstruction
n ¼ 222 43.7 ± 16.1 97.7 ± 24.8 One or more of:
 FRC >120% pred.
 RV > pred. þ 1.64 RSD
 RV/TLC > pred. þ 1.64 RSD
 FEF25e75% < pred. e 1.64 RSD
 FEF50% < pred. e 1.64 RSD
 SVCeFVC >10%
Moderate to severe; with
proximal airways obstruction
n ¼ 219 Not stated 64.3 ± 38.1 One or more of:
 FRC >120% pred.
 RV > pred. þ 1.64 RSD
 RV/TLC > pred. þ 1.64 RSD
SVCeFVC >10%
Perez et al. (2012) [26] Poorly controlled and/or
signiﬁcant dyspnoea
n ¼ 324 49 ± 17 75 ± 18 RV > predicted þ 1.64 RSD
FRC >120% predicted
Telenga et al. [28] Mild to moderate, receiving ICS n ¼ 94 43 (33e53)c 83.4 (70.9e89.5)c FEF LLN
Kulpati et al. [35] Asymptomatic (FEV1/FVC>0.7) n ¼ 25 27.9 ± 7.4 Not reported
(2.69 ± 0.37 L)
CC/TLC more than 2
SD of that of a group
of normal healthy adults
McCarthy et al. [34] Stable n ¼ 19 Range 21e50
(mean not reported)
56e112
(mean not reported)
CV/VC above normal
limits (deﬁned as
variation greater than
20% of predicted)
Impulse oscillometry (IOS) Alﬁeri et al. [21] Mild to moderate n ¼ 63 42 ± 14 92 ± 14 R5eR20 > 0.030 kPa s L1
Anderson et al. [22] British Thoracic Society
(BTS) Steps 2 to 4
n ¼ 378 BTS Step 2: 39 (37, 41)b
BTS Step 3: 41 (38, 45)b
BTS Step 4: 44 (42, 47)b
BTS Step 2: 89.8
(87.5, 92.2)b
BTS Step 3: 86.3
(81.7, 90.8)b
BTS Step 4: 83.7
(79.6, 87.8)b
R5eR20 > 0.030 kPa s L1
Manoharan et al. [24] All severities n ¼ 442 42 ± 15 86 ± 20 R5eR20 > 0.10 kPa s L1
Pisi et al. [27] All severities n ¼ 33 45 ± 15 100 ± 11 R5eR20  0.075 kPa s L1
Multiple or single-
breath nitrogen washout [36]
Gonem et al. [31] GINA Steps 3 to 5 n ¼ 37 Sacin normal 54.2 ± 3.1
Sacin high 61.2 ± 1.9
Sacin normal 83.9 ± 3.8
Sacin high 65.4 ± 4.8
Sacin > ULN, deﬁned as mean þ 1.64
SDs in age-matched control (0.204 L1)
Hanon et al. [32] Receiving 800 mg/day of
budesonide or equivalent
n ¼ 66 52 ± 17 76 ± 19 Sacin >0.12 L1
Verbanck et al. [33] Receiving budesonide n ¼ 30 43±3d 75±4d Sacin >0.12 L1
Thompson et al. [29] During asthma exacerbation,
compared with stable asthma
Exacerbation n ¼ 18
Stable n ¼ 19
Exacerbation: 33
(25e55)e
Stable: 56 (48e61)e
Exacerbation: 59
(45e75)e
Stable: 78 (70e85)e
Sacin percent predicted >ULN
HRCT Tunon-de-Lara et al. [30] Uncontrolled mild or moderate n ¼ 45 35.3 ± 10.7 89.2 ± 15.9 Air-trapping according to the deﬁnition
of the Fleischner Society [37]
FEV1 ¼ forced expiratory volume in 1 s; FEF ¼ forced expiratory ﬂow; RV ¼ residual volume; TLC ¼ total lung capacity; FRC ¼ functional residual capacity; RSD ¼ residual standard deviation; SVC ¼ slow vital capacity;
FVC ¼ forced vital capacity; ICS ¼ inhaled corticosteroid; LLN ¼ lower limit of normal; CC ¼ closing capacity; CV ¼ closing volume; IOS ¼ impulse oscillometry; R5 ¼ total airway resistance; R20 ¼ proximal airway resistance;
Sacin ¼ acinar ventilation heterogeneity; SD ¼ standard deviation; ULN ¼ upper limit of normal; HRCT ¼ high-resolution computed tomography.
a Mean ± standard deviation, unless stated otherwise.
b Mean and 95% conﬁdence interval (CI).
c Median and interquartile range.
d Mean ± standard error of the mean.
e Median and 95% CI.
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Fig. 2. Prevalence of small airways disease in reviewed studies.
O.S. Usmani et al. / Respiratory Medicine 116 (2016) 19e27 23patients without large airways obstruction (deﬁned as FEV180% of
predicted and FEV1/FVC0.7) [25]. SADwas deﬁned as the presence
of one ormore of the parameters listed in Table 1, andwas observed
in 115 (52%) of these patients. The incidence of individual SAD
criteria is shown in Fig. 3; the three hyperinﬂation criteria were
more common than airﬂow limitation (using FEF25e75%) or expira-
tory trapping.
A separate study by Perez et al. assessed the presence of hy-
perinﬂation (based on RV or FRC criteria) in 324 patients with
either poorly controlled asthma (deﬁned by the authors as ACT
<20) or signiﬁcant dyspnoea (Medical Research Council dyspnoea
score 1) [26]. Of the 324 patients, 49% had evidence of hyperin-
ﬂation according to RV, with 47% meeting the FRC criterion.
Although the prevalence was higher in patients with a lower FEV1
percent predicted (78 and 70% for RV and FRC, respectively, in pa-
tients with FEV1 <60% predicted), hyperinﬂation was observed in
more than a third of patients with normal airﬂow (34 and 40%,
respectively, in patients with FEV1 >80% predicted), which the
authors suggest indicates the involvement of small airways.Telenga et al. assessed the prevalence of small airways
obstruction in 94 patients with mild to moderate asthma receiving
ICS therapy [28]. The parameter used was FEF below the lower limit
of normal; 34 of the patients (36%) met this criterion. This subset of
patients required a signiﬁcantly higher dose of ICS than the group
with normal FEF values, and had more severe bronchial hyper-
responsiveness (assessed using a histamine challenge).
Two slightly older studies used either CC or CV to indicate the
presence of SAD. In the ﬁrst study, McCarthy et al. recruited 19
patients with asthma during a symptom-free period [34]. Of these,
eleven (57.9%) had an increased CV/VC ratio (deﬁned as variation
greater than 20% of predicted). The investigators were unable to
determine the CV in a further ﬁve patients e including these in the
deﬁnition of SAD increased the prevalence to 84%. In the second
study, Kulpati et al. recruited 100 subjects into four groups e 25
normal, healthy adults, 25 asymptomatic smokers, 25 patients with
asymptomatic asthma, and 25 symptomatic smokers [35]. All par-
ticipants had to have FEV1/FVC >70%. Within the asthma group, 5/
25 (20%) had CC/TLC% more than 2 SD of that of the healthy
Fig. 3. Incidence of small airways obstruction by individual parameters in a population without (grey bars) or with (black bars) proximal airways impairment (adapted from Perez
et al. [25]).
O.S. Usmani et al. / Respiratory Medicine 116 (2016) 19e2724participants. The authors suggest that CC/TLC is more sensitive than
CV/VC for detecting small airways dysfunction.3.2. Prevalence using impulse oscillometry
Alﬁeri et al. recruited 63 patients with mild-to-moderate
asthma, deﬁning SAD as R5eR20 above the upper limit of normal
(ULN) of 0.030 kPa s L1 [21]. Thirty patients (47.6%) met this
deﬁnition; these patients were older, more likely to be female, non-
atopic and to have uncontrolled asthma (ACT score 19). Anderson
et al. also used R5eR20 > 0.030 kPa s L1 in their retrospective
analysis, describing this threshold as ‘the upper bound of the 95% CI
in a previously reported group of healthy subjects’ [22]. Patients
were stratiﬁed by British Thoracic Society (BTS) management stage:
Step 2 (low-to-moderate ICS dose); Step 3 (low-to-moderate ICS
dose plus a second controller); Step 4 (high dose ICS), with the
prevalence of abnormal R5eR20 values being 64.6%, 63.5% and
69.9%, respectively.
In contrast, Pisi et al. used a value of 0.075 kPa s L1 as the
threshold for SAD, describing this as ‘a conservative upper limit of
normal’ [27]. They recruited 33 patients with normal FEV1, 11 of
whom (33%) met the criterion for SAD. In all patients, R5eR20 was
signiﬁcantly (p < 0.05) related to the ratio of FVC/SVC, FEF25e75%
and ACT. Fourteen of the 33 patients had at least one mild to
moderate exacerbation in the prior year; SAD prevalence was
signiﬁcantly higher (p¼ 0.013) in the exacerbators (57%), compared
to the non-exacerbators (19%).
In the analysis of data from patients undergoing screening for
clinical trials mentioned in the previous section, Manoharan et al.
also used an arbitrary R5eR20 cut-point of 0.1 kPa s L1 to deﬁne
the presence of SAD [24]. Of the 442 patients analysed, 185 (42%)
had evidence of SAD. These patients were signiﬁcantly older, with
worse lung function (FEV1 and FEF25e75%) than those without SAD.3.3. Prevalence using nitrogen washout
Gonem et al. recruited 37 patients with asthma and 17 age-
matched healthy controls, deﬁning the ULN for Sacin as the
mean þ 1.64 SDs in the control group e a value of 0.204 L1 [31].
Using this value,17 of the patients with asthma (46%) had high Sacin.
Compared with the patients with asthma and no SAD, these pa-
tients were signiﬁcantly more likely to have lower FEV1% predicted
and FEV1/FVC, and higher FRC, RV/TLC and lung clearance index.
Hanon et al. investigated switching patients with stable asthma
from a conventional-particle ICS formulation to a small particle ICS
formulation [32]. Eligible patients had abnormal Sacin, deﬁned as
>0.12 L1 at the study screening visit. The researchers screened 66
patients to recruit 35 eligible patients e suggesting a prevalence of
abnormal values of 53%.
A Sacin cut-off of 0.12 L1 was also used by Verbanck et al. in a
study of 30 patients with a wide range of asthma severities, all
receiving a dry powder formulation of budesonide for at least 6
weeks prior to entry [33]. Sixteen patients (53%) had abnormal
baseline Sacin values. On being switched from the dry powder to an
aerosol formulation preferentially distributed to the peripheral
airways [38], there was a signiﬁcant improvement (p < 0.05) in
mean Sacin in the group with abnormal baseline Sacin values, but no
change in the group with normal values.
Thompson et al. recruited 18 consecutive patients admitted to a
hospital with severe asthma exacerbations, conducting spirometry
and multiple-breath nitrogen washout tests within 48 h of admis-
sion [29], and deﬁned SAD as Sacin above the ULN from an earlier
study [39]. Nineteen patients with stable asthma (ACQ<0.75) were
recruited for comparison. Of the patients admitted for an exacer-
bation, 11 (61%) had Sacin >ULN; this was not signiﬁcantly different
to the stable asthma controls, in whom 14 (74%) had values >ULN.
When the two groups of patients were combined, there was a
signiﬁcant relationship between Sacin and FEV1 percent predicted
(Spearman rank order correlation coefﬁcient, rs¼0.57, p < 0.001),
although even some patients with normal FEV1 values had
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Global Initiative for Asthma (GINA) 2011 Step and Sacin in the
exacerbation group (rs ¼ 0.59, p ¼ 0.016); a regression analysis was
not performed in the stable asthma group as most of the patients
were in GINA Steps 3 or 4.
3.4. Prevalence using HRCT
In the only study identiﬁed that reported prevalence using
HRCT, 58 patients with uncontrolledmild or moderate asthmawere
recruited [30]. HRCTevaluations were conducted, and patients with
air-trapping were randomized to different ICS treatments. The au-
thors report demographic data for 20 patients without air-trapping
and 25 patients with air trapping, suggesting a SAD prevalence of
56%. There were no signiﬁcant differences between these groups
for any demographic characteristics.
4. Discussion
The small airways are currently highly topical, with the resur-
gence of interest in assessing the ‘silent zone’ driven by enhanced
physiological and imaging detection systems, coupled with inno-
vation in pharmaceuticals to target inhaled drugs to this region, in
order to evaluate the relevance of this area in day-to-day clinical
practice [2,8]. Although evidence from clinical trials on treatment
targeted to the small airways is mixed, ‘real life’ research has shown
potential beneﬁt on asthma control and quality of life [13,14],
where the corticosteroid dose can be signiﬁcantly reduced with
small particles and achieve as good as an effect as large particles.
However, there are limited data available on the prevalence of small
airways disease in patients with asthma.
To our knowledge this is the ﬁrst systematic literature review to
assess the prevalence of SAD in patients with asthma. We ascer-
tained that most studies consistently observed between 50 and 60%
of patients with asthma displaying evidence of SAD, with SAD
existing across the entire spectrum of asthma severity, including
patients with normal FEV1 [29], and patients with little or no
proximal airﬂow obstruction [25]. This supports the notion that
conventional spirometric methods of assessing airways function in
the clinic cannot reliably and sensitively evaluate small airways
dysfunction.
It is apparent in our review that there is variation in the selec-
tion of endpoints used to deﬁne the presence of SAD. Different
researchers use different threshold criteria for the same endpoints,
including population values, disease-speciﬁc or study-speciﬁc, and
(arbitrary) ﬁxed values. Further, the studies that used more sensi-
tive measures of airway function (such as IOS, nitrogen washout
and HRCT) tended to recruit smaller numbers of patients. To add to
this complexity, the reported studies recruited populations with
very different patient characteristics. Indeed, Anderson et al. found
the prevalence of SAD in patients with populations of differing
asthma severity, as deﬁned by their need for asthma treatment, was
approximately two-thirds across all BTS treatment steps 2e4,
despite all patients in these steps having a normal FEV1, suggesting
that conventional inhaled therapy was unable to attenuate SAD
[22]. Unfortunately the study by Anderson et al. was the only one to
report prevalence data for different disease severities, and this
study did not recruit patients with mild, intermittent (i.e., BTS
treatment step 1) asthma. We are therefore unable to estimate
whether prevalence could be higher in very mild or very severe
disease e and are also unable to conclude on the relative preva-
lence of SAD in different levels of asthma severity using other
methods.
Another question that has been raised is whether SAD occurs
when inﬂammation is present, or when there is functionalimpairment. A number of studies have shown that tissue inﬂam-
mation in the small airways correlates with symptoms. For
example, Kraft et al. evaluated the level of inﬂammatory cells taken
from bronchial biopsies, showing that the levels in the alveolar
tissues (and not proximal tissues) correlated with nocturnal
symptoms [3]. This is supported by data showing that small particle
ICS improve symptoms compared with standard particle ICS (sug-
gesting that the effect is at least partly due to reduced inﬂammation
in the small airways) [10]. Other studies, including Manoharan
et al., have shown that functional measures of SAD correlate with
the extent of symptoms and asthma control [40]. It is likely,
therefore, that the clinical impact of SAD is due to a mixture of
inﬂammation and functional changes within the small airways.
Our systematic literature review has highlighted the need for a
‘gold standard’ deﬁnition for SAD. The methodological techniques
used in these studies to identify SAD are indirect assessments, with
few evaluations able to directly measure disease in the small air-
ways. Unlike spirometry, which over many decades has led to the
development of population data on measures such as FEV1 that are
utilised as endpoints in clinical trials and in respiratory diagnosis,
many of the SAD assessments are in their relative infancy, although
population data is being generated [41e43].
Although none of the identiﬁed studies used FVC alone to
evaluate the prevalence of SAD, in a study of patients enrolled into
the National Heart, Lung, and Blood Institute’s Severe Asthma
Research Program, there was a statistically signiﬁcant correlation
between FVC and RV/TLC (Pearson correlation coefﬁcient,
r ¼ 0.64; p < 0.0001) [44]. This suggests (at least at a group level)
that FVC might have some utility in assessing SAD, especially since
FVC can be easily assessed by primary care physicians, so could be
undertaken as a serial assessment to monitor SAD. Indeed, FVC is
considered to have high reproducibility and low variability, corre-
lating well with small airways obstruction, in contrast to FEF25e75%,
which has low reproducibility and is inﬂuenced by large airway
obstruction. In the only study to determine the prevalence of SAD
by both IOS and spirometry, Manoharan et al. reported values of
42% using IOS and 54% using FEF25e75%, suggesting that the two
methods are not comparable e although admittedly this analysis
used arbitrary values to deﬁne the presence of SAD [24]. In contrast,
Pisi et al. [27] showed that R5eR20 was signiﬁcantly (p < 0.05)
related to FVC/SVC and FEF25e75%, suggesting that these spirometric
parameters can at least give an indication of the presence of SAD.
However, in the study by Perez et al., in patients without proximal
airways impairment SAD prevalence according to airﬂow limitation
(i.e., FEF25e75%) was under-reported in comparison to hyperinﬂa-
tion criteria, suggesting that spirometry (speciﬁcally FEF) is a
relatively inaccurate method of determining the presence of SAD
[25]. Indeed, the American Thoracic Society has advised that
FEF25e75% should not be used to diagnose SAD [45], and the FEF-
based prevalence data that we present here therefore need to be
interpreted with caution. In contrast, closing volume (from single
nitrogen washout) has been shown to have good sensitivity to
detect small airways inﬂammation, even relatively early in the
pathologic process [46]. However, such measurements are not
commonly used in everyday clinical practice as they are complex to
administer and interpret, and have a high degree of variability
compared to FEV1.
Indeed, in a similar manner to composite scoring systems such
as the BODE index in COPD [47] to identify particular patient
characteristics, work is currently underway to determine whether
composite indices of SAD may identify a small airways phenotype.
Indeed, one study has suggested that IOS (described as effort-
independent) and spirometry (effort-dependent) may provide
‘distinct yet complimentary’ data on the presence and impact of
SAD, which suggests that combining these types of measures into a
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type’ has previously been described as being individuals with not
optimally controlled asthma (ACQ >1.5, symptoms, regular use of
reliever medication, or failure to respond to ICSs and LABAs), but
with relatively normal spirometry values [16]. Although in the
HRCT study there were no differences in demographic character-
istics between the groups with or without air trapping [30], other
studies have described correlations between SAD and asthma
control (ACT score) [21], exacerbations [27], or bronchial hyper-
responsiveness [28]. Despite the challenges in its measurement,
these ﬁndings highlight the potential beneﬁts of determining the
presence of SAD, and could enable appropriate targeting of phar-
macotherapy. The ongoing longitudinal AssessmenT of smalL Air-
ways involvemeNT In aSthma (ATLANTIS) study will further
enhance our knowledge of the prevalence of small airway disease
in asthma [48].
In conclusion, studies conducted using different techniques to
assess SAD collectively indicate that SAD is prevalent across the
range of asthma disease severity, even in patients with milder
disease. Given its clinical impact, the presence of SAD should not be
underestimated or overlooked as part of the management of pa-
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